INMB: Rega marang dodolan INmune Bio Inc
Global isolation of countries is hindering international testing of new drugs, which underscores the significance of the price-to-sales multiple. The value of 767.40 aligns with the current metric, capturing market expectations. However, sanctions and overseas patent complexities create risks for INmune Bio, Inc. (INMB). Meanwhile, colossal demand for Alzheimer's therapy opens vast growth prospects for the developer of selective inhibitors.
INmune Bio Corp (INMB) - rincian metrik lan laporan keuangan
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- statistik kawajiban utang lan likuiditas:
Rasio Total Utang marang Ekuitas INmune Bio, Inc.|INMB - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal INmune Bio Corporation|INMB - Utang perusahaan|Rasio utang marang nilai buku INmune Bio Corp|INMB - Utang jangka dawa perusahaan|Utang jangka cendhak INmune Bio|Rasio jangkoan perantara inmunebio.com
- data bathi resik lan rasio valuasi:
INMB - Bathi resik|Bathi sing dikarepake INmune Bio, Inc.|INMB - Pangali P/E|Kapitalisasi marang proyeksi bathi INmune Bio Inc|INMB - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan INmune Bio Corp|INMB - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajroning taun lumaku INmune Bio|INMB - Bathi resik saben saham (EPS TTM)|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan inmunebio.com|INMB - Wutah bathi saben saham ing taun lumaku|Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep INmune Bio, Inc.
- data total pendapatan lan volume dodolan:
Analisis fundamental perusahaan:inmunebio.com (INMB)
P/S reflects the ratio of market capitalization to gross revenue, determining the cost per unit of revenue. Analyzing P/S volatility allows an investor to identify asset overbought conditions or the risk of capital freeze through historical context. This indicator is critical for assessing resource efficiency. For INmune Bio, Inc. (INMB), it reflects market expectations for future licensing deals with Big Pharma in the absence of current M&A strategies.
Perusahaan pesaing
argenx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S BNTX (BioNTech)|Abivax Pharma (ABVX) - Rega marang dodolan|ADMA Bio - Multiplikator P/S|Koefisien rega marang pendapatan Protagonist Corp PTGX|Immunovant, Inc. (IMVT) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan KNSA|Rasio rega marang pendapatan Grifols|Kapitalisasi marang pendapatan Adaptive Biotech (ADPT)|Kapitalisasi marang pendapatan CLDX (Celldex)|Multiplikator P/S Aurinia Corp (AUPH)|Rasio rega marang pendapatan BioCryst BCRX|VERA: Rasio kapitalisasi marang pendapatan|Dianthus Therapeutics, Inc. - Multiplikator P/S|Rega marang dodolan Pharvaris NV|ABCL (AbCellera Biologics Inc) - Kapitalisasi marang pendapatan|Tourmaline - Rasio kapitalisasi pasar marang pendapatan|PGEN (Precigen, Inc.) - Multiplikator P/S|Rasio rega marang pendapatan PHAR|Multiplikator P/S NKTR|Koefisien rega marang pendapatan Upstream Bio, Inc.|Rasio rega marang pendapatan Zenas Biopharma, Inc. ZBIO|Immunome Bio (IMNM) - Rega marang dodolan|GOSS: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan KALV (kalvista.com)|SEPN: Multiplikator P/S|PVLA - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Savara Corp|Rasio kapitalisasi marang pendapatan RIGL (Rigel Corp)|Multiplikator P/S ANAB|Kapitalisasi marang pendapatan astriatx.com ATXS|enGene - Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan RAPT Therapeutics Inc. (RAPT)|Aerovate - Multiplikator P/S|Koefisien rega marang pendapatan Aclaris Therapeutics, Inc ACRS|Kyverna Therapeutics (KYTX) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan TLSA|Rasio rega marang pendapatan Cabaletta Bio|Kapitalisasi marang pendapatan Ventyx Biosciences Inc. (VTYX)|Multiplikator P/S THTX|Rasio rega marang pendapatan AVTX (Avalo Therapeutics Inc)|Rasio rega marang pendapatan Eledon Pharmaceuticals ELDN|AGEN (agenusbio.com) - Rasio rega marang dodolan|Climb Bio - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan ZURA (Zura Bio Ltd)|ATYR: Multiplikator P/S|Adagene Inc. (ADAG) - Multiplikator P/S|Rasio rega marang pendapatan ImageneBio|STTK: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Equillium, Inc. (EQ)|Kapitalisasi marang pendapatan connectbiopharm.com CNTB|Multiplikator P/S IMUX (Immunic)|Multiplikator P/S Atara Biotherapeutics, Inc. ATRA|IFRX: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan XFOR (x4pharma.com)|ACET: Multiplikator P/S|CELU - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Barinthus Bio|Kapitalisasi marang pendapatan Kezar Life Sciences Inc (KZR)|Rasio rega marang pendapatan SAB Biotherapeutics (SABS)|Kapitalisasi marang pendapatan akaritx.com AKTX|Enlivex Therapeutics Ltd. - Kapitalisasi marang pendapatan|Multiplikator P/S Q32 Bio Inc QTTB|GOVX - Rasio rega marang pendapatan|EDSA (Edesa Biotech Corp) - Rasio kapitalisasi marang pendapatan|IBIO: Multiplikator P/S|Rega marang dodolan Carisma Therapeutics Inc. (CARM)|XTLB (XTL Biopharmaceuticals Ltd.) - Multiplikator P/S|Bolt Bio (BOLT) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan HCW Biologics Inc. (HCWB)|aptevotherapeutics.com - Rasio kapitalisasi marang pendapatan|Rasio rega marang pendapatan AIM ImmunoTech Inc. AIM|ADTX - Kapitalisasi marang pendapatan|GRI: Kapitalisasi marang pendapatan|XRTX - Multiplikator P/S|ReShape Lifesciences (HIND) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan REVB|INDP (Indaptus Therapeutics) - Multiplikator P/S|Rega marang dodolan scinai.com SCNI|Kapitalisasi marang pendapatan CALI (CalciMedica, Inc.)|AFMD (affimed.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ALLK (Allakos)|HOOKIPA Pharma, Inc. - Rasio rega marang pendapatan|IGM Bio - Multiplikator P/S|Koefisien rega marang pendapatan iteostherapeutics.com ITOS|Ocean Biomedical (OCEA) - Rasio rega marang pendapatan|Rega marang dodolan TC BioPharm (Holdings) Plc (TCBP)|Kapitalisasi marang pendapatan THRD
